Squeeze flow and compaction behavior of toughened polyimide matrix composites

The main emphasis was placed upon the squeeze flow and compaction behavior of the Lewis Research Center (LaRC) research project series polyimide matrix composites. The measurement of squeeze film flow behavior was performed by a plastometer which monitors the change of thickness of a prepreg specimen laid between two parallel plates under the specified temperature and pressure history. A critical evaluation of the plastometer data was attempted by examining the morphology of the specimen at various points during the squeeze flow. The effects of crosslinks (Mc) of resin, imidization (B-ataging) condition, and pressure on the squeeze flow behavior were examined. Results are given

European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome, in the right population.

In clinical practice and for scientific purposes, cardiologists and primary care physicians perform risk assessment in patients with cardiac diseases or conditions with high risk of developing such. The European Heart Rhythm Association (EHRA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and the Latin American Heart Rhythm Society (LAHRS) set down this expert consensus statement task force to summarize the consensus regarding risk assessment in cardiac arrhythmias. Objectives were to raise awareness of using the right risk assessment tool for a given outcome in a given population, and to provide physicians with practical proposals that may lead to rational and evidence-based risk assessment and improvement of patient care in this regard. A large variety of methods are used for risk assessment and choosing the best methods and tools hereof in a given situation is not simple. Even though parameters and test results found associated with increased risk of one outcome (e.g. death) may also be associated with higher risk of other adverse outcomes, specific risk assessment strategies should be used only for the purposes for which they are validated. The work of this task force is summarized in a row of consensus statement tables

The Changing Landscape for Stroke\ua0Prevention in AF: Findings From the GLORIA-AF Registry Phase 2

Background GLORIA-AF (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation) is a prospective, global registry program describing antithrombotic treatment patterns in patients with newly diagnosed nonvalvular atrial fibrillation at risk of stroke. Phase 2 began when dabigatran, the first non\u2013vitamin K antagonist oral anticoagulant (NOAC), became available. Objectives This study sought to describe phase 2 baseline data and compare these with the pre-NOAC era collected during phase 1. Methods During phase 2, 15,641 consenting patients were enrolled (November 2011 to December 2014); 15,092 were eligible. This pre-specified cross-sectional analysis describes eligible patients\u2019 baseline characteristics. Atrial fibrillation disease characteristics, medical outcomes, and concomitant diseases and medications were collected. Data were analyzed using descriptive statistics. Results Of the total patients, 45.5% were female; median age was 71 (interquartile range: 64, 78) years. Patients were from Europe (47.1%), North America (22.5%), Asia (20.3%), Latin America (6.0%), and the Middle East/Africa (4.0%). Most had high stroke risk (CHA2DS2-VASc [Congestive heart failure, Hypertension, Age  6575 years, Diabetes mellitus, previous Stroke, Vascular disease, Age 65 to 74 years, Sex category] score  652; 86.1%); 13.9% had moderate risk (CHA2DS2-VASc = 1). Overall, 79.9% received oral anticoagulants, of whom 47.6% received NOAC and 32.3% vitamin K antagonists (VKA); 12.1% received antiplatelet agents; 7.8% received no antithrombotic treatment. For comparison, the proportion of phase 1 patients (of N = 1,063 all eligible) prescribed VKA was 32.8%, acetylsalicylic acid 41.7%, and no therapy 20.2%. In Europe in phase 2, treatment with NOAC was more common than VKA (52.3% and 37.8%, respectively); 6.0% of patients received antiplatelet treatment; and 3.8% received no antithrombotic treatment. In North America, 52.1%, 26.2%, and 14.0% of patients received NOAC, VKA, and antiplatelet drugs, respectively; 7.5% received no antithrombotic treatment. NOAC use was less common in Asia (27.7%), where 27.5% of patients received VKA, 25.0% antiplatelet drugs, and 19.8% no antithrombotic treatment. Conclusions The baseline data from GLORIA-AF phase 2 demonstrate that in newly diagnosed nonvalvular atrial fibrillation patients, NOAC have been highly adopted into practice, becoming more frequently prescribed than VKA in Europe and North America. Worldwide, however, a large proportion of patients remain undertreated, particularly in Asia and North America. (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients With Atrial Fibrillation [GLORIA-AF]; NCT01468701

Indoor Thermal Environment of Temporary Mobile Energy Shelter Houses (MeSHs) in South Korea

Temporary housing must be developed to support the long-term residence needs of disaster victims. The present study assesses a temporary housing unit, the so-called Mobile Energy Shelter House (MeSH), incorporating the “Korean Dwelling Insulation Standard” in order to reduce energy usage for cooling and heating. To assess energy performance, the characteristics of the indoor thermal environment were measured during the winter and summer seasons. In summer, at maximum insolation, the outdoor temperature was 37.6 °C and the indoor temperature of the MeSH ranged from 18 to 24 °C when the cooling system was not used. Conversely, during winter, the average outdoor temperature was −11.3 °C and the indoor temperature ranged from 16.09 to 20.63 °C when a temperature-controlled floor-heating was installed. Furthermore, the Predicted Mean Vote (PMV) was adopted to determine whether the ISO 7730 comfort criterion (i.e., PMV range from −0.5 to +0.5) was achieved. Based on the calculations presented here, PMV in summer ranged from −1.21 to +1.07 and that in winter ranged from −0.08 to −0.85, suggesting that the thermal environment is not always comfortable for occupants in either summer or winter. Nevertheless, the ISO comfort criterion can be achieved through varying air velocity in summer and changing clothing characteristics in winter. A comparison between yearly energy demand of existing characteristic temporary housing (Shelter House) and the MeSH modules used in this study was performed. The simulation results show a 60% difference in energy demand between MeSH and existing temporary housing shelter houses